Aytu BioPharma Statistics
Total Valuation
Aytu BioPharma has a market cap or net worth of $12.52 million. The enterprise value is $15.96 million.
Important Dates
The last earnings date was Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Aytu BioPharma has 6.17 million shares outstanding. The number of shares has increased by 52.64% in one year.
| Current Share Class | 6.17M |
| Shares Outstanding | 6.17M |
| Shares Change (YoY) | +52.64% |
| Shares Change (QoQ) | -3.31% |
| Owned by Insiders (%) | 2.81% |
| Owned by Institutions (%) | 5.29% |
| Float | 4.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 1.59 |
| PS Ratio | 0.15 |
| Forward PS | 0.36 |
| PB Ratio | 0.35 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 9.74 |
| EV / Sales | 0.21 |
| EV / EBITDA | 2.46 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.61.
| Current Ratio | 1.03 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 2.43 |
| Debt / FCF | n/a |
| Interest Coverage | -0.06 |
Financial Efficiency
Return on equity (ROE) is -1.23% and return on invested capital (ROIC) is -0.38%.
| Return on Equity (ROE) | -1.23% |
| Return on Assets (ROA) | -0.16% |
| Return on Invested Capital (ROIC) | -0.38% |
| Return on Capital Employed (ROCE) | -0.60% |
| Revenue Per Employee | $761,676 |
| Profits Per Employee | $16,069 |
| Employee Count | 102 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 2.16 |
Taxes
In the past 12 months, Aytu BioPharma has paid $743,000 in taxes.
| Income Tax | 743,000 |
| Effective Tax Rate | 219.82% |
Stock Price Statistics
The stock price has decreased by -30.95% in the last 52 weeks. The beta is -0.10, so Aytu BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.10 |
| 52-Week Price Change | -30.95% |
| 50-Day Moving Average | 1.25 |
| 200-Day Moving Average | 1.75 |
| Relative Strength Index (RSI) | 66.09 |
| Average Volume (20 Days) | 3,611,339 |
Short Selling Information
The latest short interest is 135,760, so 2.20% of the outstanding shares have been sold short.
| Short Interest | 135,760 |
| Short Previous Month | 118,651 |
| Short % of Shares Out | 2.20% |
| Short % of Float | 3.05% |
| Short Ratio (days to cover) | 3.84 |
Income Statement
In the last 12 months, Aytu BioPharma had revenue of $77.69 million and earned $1.64 million in profits.
| Revenue | 77.69M |
| Gross Profit | 51.56M |
| Operating Income | -321,000 |
| Pretax Income | -12.61M |
| Net Income | 1.64M |
| EBITDA | 6.48M |
| EBIT | -321,000 |
| Earnings Per Share (EPS) | -$0.83 |
Full Income StatementBalance Sheet
The company has $18.17 million in cash and $21.42 million in debt, giving a net cash position of -$3.25 million or -$0.53 per share.
| Cash & Cash Equivalents | 18.17M |
| Total Debt | 21.42M |
| Net Cash | -3.25M |
| Net Cash Per Share | -$0.53 |
| Equity (Book Value) | 34.90M |
| Book Value Per Share | 5.66 |
| Working Capital | 1.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.53 million and capital expenditures -$211,000, giving a free cash flow of -$5.74 million.
| Operating Cash Flow | -5.53M |
| Capital Expenditures | -211,000 |
| Free Cash Flow | -5.74M |
| FCF Per Share | -$0.93 |
Full Cash Flow StatementMargins
Gross margin is 66.36%, with operating and profit margins of -0.41% and 2.11%.
| Gross Margin | 66.36% |
| Operating Margin | -0.41% |
| Pretax Margin | 0.44% |
| Profit Margin | 2.11% |
| EBITDA Margin | 8.34% |
| EBIT Margin | -0.41% |
| FCF Margin | n/a |